Hims & Hers Health Inc (NYSE: HIMS) Offers Online Mental Health Therapy Services, DHT Holdings Inc (NYSE: DHT) Buys Back Its Shares & Akebia Therapeutics Inc (NASDAQ: AKBA) Announces Grants Inducement

Hims & Hers Health Inc (NYSE: HIMS) made an official announcement of its expansion plans. In addition to the mental health services, the company will provide individual online therapy as part of its scale-up operations. As a result, patients can access online psychiatry help and take advantage of support group sessions provided under the gambit of new individualized therapy. Additionally, patients can take advantage of the online services for a pocket-friendly cost. According to reports, individual online therapy is available at $99 per session.

Here’s what the Hims & Hers Health Inc will offer as part of the services

The online psychiatry services will give the individual patient access to healthcare providers capable of prescribing medications. Drugs will be prescribed for depression, anxiety, and stress, among others, on a case-to-case basis. As part of the service, the patient who wishes to use the services will be connected to a licensed therapist over a video call. The medical professional, after a thorough analysis, will suggest a mental wellness routine for the patient. 

“In business, we talk a lot about supply and demand, but until I started working in the healthcare industry I had never seen those two concepts so critically out of balance,” commented Andrew Dudum, co-founder and CEO of Hims & Hers.

DHT Holdings Inc (NYSE: DHT) purchased its share as part of the buyback

As part of its share buyback, DHT Holdings Inc (NYSE: DHT) has purchased its company shares. Under the arrangement, the company has purchased more than 3.72 million shares, which is on par with 2.2% of its outstanding shares. The shares were purchased between May 17, 2021, and June 7, 2021, and retired upon receipt.

Akebia Therapeutics Inc (NASDAQ: AKBA) has initiated inducement grants for 25 of its employees

Akebia Therapeutics Inc (NASDAQ: AKBA), under the Nasdaq listing rule 5635(c)(4), announced that it had initiated the process of inducement grants for 25 employees. The biopharmaceutical company provided its newly-hired employees with the option to purchase an aggregate of 210,000 shares of Akebia’s common stock. The company set a deadline for the purchase.

Leave a Comment

Your email address will not be published.